A Phase 3 Randomized, Double-blind, Multi-center Study of Adjuvant Nivolumab versus Placebo in Subjects with High Risk Invasive Urothelial Carcinoma
This is a phase 3, randomized, double-blind, multicenter trial of adjuvant nivolumab versus placebo in adult male or female subjects who have undergone radical resection of IUC originating in the bladder or upper urinary tract (renal pelvis or ureter) and are at high risk of recurrence:
Study Number: 

PH 284416

Principal Investigator: 
ClinicalTrials.Gov ID: 

To inquire about participating in these studies, call 1-877-ASK-RPCI (1-877-275-7724) or e-mail askrpci@roswellpark.org.